Skip to main
CSTL

CSTL Stock Forecast & Price Target

CSTL Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Castle Biosciences Inc. is experiencing significant growth in its TissueCypher test, with test volume expanding by 92% year-over-year and 23% quarter-over-quarter in 2Q25, likely aided by a strengthened sales force. The company has also improved the gross margin of the TissueCypher test, achieving an impressive 77% gross margin in Q3, which indicates robust profitability. With ongoing expansions in sales and a mature gastrointestinal sales force anticipated by the second half of 2025, Castle Biosciences is positioned for continued revenue growth in its gastrointestinal diagnostics segment.

Bears say

Castle Biosciences Inc. faces a negative outlook due to concerns over its expected revenue multiples, particularly for its dermatology and DecisionDx-UM tests, which are anticipated to be significantly lower than those for the TissueCypher product. Management highlighted a lack of clinician awareness regarding these tests as a critical barrier to market penetration, suggesting that current growth may be hindered by insufficient adoption in key segments. Additionally, while the stock may seem undervalued based on conservative estimates, the persistent challenges in clinician engagement and product awareness could limit future revenue growth and investor confidence.

CSTL has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Castle Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Castle Biosciences Inc (CSTL) Forecast

Analysts have given CSTL a Strong Buy based on their latest research and market trends.

According to 6 analysts, CSTL has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Castle Biosciences Inc (CSTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.